PPIDT00451
Drug Information
| Name | Agalsidase alfa |
|---|---|
| Sequence | LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMALWAIMAAPLFMSNDLRHISPQAKALLQDKDVIAINQDPLGKQGYQLRQGDNFEVWERPLSGLAWAVAMINRQEIGGPRSYTIAVASLGKGVACNPACFITQLLPVKRKLGFYEWTSRLRSHINPTGTVLLQLENTMQMSLKDLL |
| DrugBank_ID | DB15874 |
| Type | biotech |
| Indication | Agalsidase alfa is indicated in the treatment of Fabry disease.[L16398] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Capsule | Oral |
600 umol/1
|
| Injection, solution, concentrate | Intravenous |
1 MG/ML
|
| Solution | Intravenous |
1 mg / mL
|
| Solution, concentrate | Intravenous |
3.5 mg
|
| Solution | Intravenous |
1.0 mg/mL
|